Trial Profile

A Phase 1, Open-Label, Multicenter, Drug-Drug Interaction Study of TAK-788 and Midazolam, a Sensitive CYP3A Substrate, in Patients With Advanced Non-Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mobocertinib (Primary) ; Midazolam; Midazolam
Indications Non-small cell lung cancer
Focus Pharmacokinetics
Sponsors Takeda Oncology

Most Recent Events

09 Aug 2022 Results of safety analysis and PK assessment presented at the 2022 World Conference on Lung Cancer
14 Feb 2022 Status changed from active, no longer recruiting to completed.
12 Aug 2021 Planned End Date changed from 11 Aug 2021 to 11 Jan 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com